top of page
Welcome to
Gateway Pharmaceutical

Gateway Pharmaceutical is a specialty company focusing on 505(b)(2) new NDAs of antibiotics for target delivery of drugs to local bacteria, to improve efficacy and reduce antibiotic resistance.

​

Our Team has extensive pharmaceutical industrial experience in pharmaceutical CMC, product development, manufacturing,  pharmacokinetics, clinical design and studies, and regulatory submission. 

Our Mission

Innovating site-specific delivery of antibiotics to combat antibiotic resistance threats to the United States and the World.

bio_stl_award.jpg

BioSTL Award in 2018 Venture Showcase

September, 2020  We received the NIH NIAID Pre-Clinical Service Award on GMP manufacturing of Metronidazole Delayed-Release Capsules for treating Clostridium difficile infection.

 

March, 2020  Our key colon-delivery patent  10,588,864 received approval from the US PTO. 

​

August, 2018 – We received the NIH SBIR Phase I grant on Metronidazole Colon-Delivery for treating Clostridium difficile Infection. 

​

November, 2018  Gateway won the BioSTL Award on the 10th Startup Connection Venture Showcase in St. Louis. 

Contact Us

Thanks for submitting!

©2020 by Gateway Pharmaceutical

All Rights Reserved.

bottom of page